Abstract
NEW YORK Revvity's Euroimmun subsidiary is expanding its fungal disease testing menu with molecular tests to aid the detection of a broader range of pathogens and genetic markers of drug resistances.
Key Data
-
Publication Date20 February 2025
-
Primary AuthorGreg Cima
-
Source360Dx
-
LanguageEnglish
Click below to visit original source: